Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 1, 2017Journal of Comparative Effectiveness ResearchOpen Access

Indication-specific pricing of pharmaceuticals in the US healthcare system

View Full Paper
Ask AI
Bookmark
Share

Authors

SPSteven D. PearsonUniversity of Maryland, BaltimoreWDWilliam B DreitleinInstitute for Clinical and Economic ReviewCHChris HenshallOffice Of Health Economics

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Pearson et al. (2017) studied this question.

synapsesocial.com/papers/6a993b8008ab6325d2e12e24https://doi.org/10.2217/cer-2017-0018
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Indication-Specific Pricing for Cancer Drugs2014 · 129 citations
  2. 2Reform of the Buy-and-Bill System for Outpatient Chemotherapy Care Is Inevitable: Perspectives from an Economist, a Realpolitik, and an Oncologist2015 · 27 citations